Cathay International Holdings Ld Total Voting Rights (6298D)
29 October 2020 - 9:43PM
UK Regulatory
TIDMCTI
RNS Number : 6298D
Cathay International Holdings Ld
29 October 2020
29 October 2020
Dissemination of a Regulatory Announcement that contains inside
information according to REGULATION (EU) No 596/2014 (MAR).
Cathay International Holdings Limited
Total Voting Rights
In conformity with Rule 5.6.1 of the Disclosure Guidance and
Transparency Rules, we notify the market that as at 28 October 2020
Cathay International Holdings Limited's capital consisted of
1,913,812,399 common shares of USD 0.01 each ("Common Shares") and
8,947,200 A shares of USD 0.01 each ("A Shares").
The A Shares and the Common Shares rank equally in all respects
save that each A Share carries 20 votes and each Common Share
carries one vote. A Shares are convertible into Common Shares on a
one for one basis in accordance with the Bye-Laws of the
Company.
Only the Common Shares are admitted to trading.
Accordingly, the total number of voting rights attached to the
Common Shares is 1,913,812,399 and this figure should be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, Cathay International Holdings
Limited under the Disclosure Guidance and Transparency Rules
-Ends-
For further enquiries, please contact:
Cathay International Holdings Limited
Eric Siu (Finance Director) Tel: +852 2828 9289
Patrick Sung (Director and Controller)
SPARK Advisory Partners Limited (Financial
Advisor) Tel: +44 (0) 20 3368 3555
Andrew Emmott / James Keeshan
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main
market listed investment holding company and an operator and
investor in the healthcare sector in the People ' s Republic of
China (the " PRC " ). The Company and its subsidiaries
(collectively the " Group " ) aim to leverage on investment
opportunities in the growing domestic demand for high quality
healthcare products in the PRC and build portfolio companies into
market sector leaders with competitive edge. Cathay has already
demonstrated a track record of identifying investment opportunities
in this area including: Lansen, a leading specialty pharmaceutical
company focused on rheumatology and dermatology in the PRC; Haizi,
a company engaged in the manufacture, marketing and sale of
inositol and its by-product, di-calcium phosphate; Natural
Dailyhealth, a company engaged in production and sales of plant
extracts for use as key active ingredients in healthcare products;
and Botai, a company engaged in collagen products.
The Group employs approximately 1,300 people across the PRC,
including over 2 0 specialist corporate and business development
staff based at the holding c ompany ' s offices in Hong Kong and
Shenzhen. Cathay also has a hotel investment. For more information
please visit the Company ' s website: www.cathay-intl.com.hk .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRBGBDGBSDDGGC
(END) Dow Jones Newswires
October 29, 2020 06:43 ET (10:43 GMT)
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From Apr 2024 to May 2024
Cathay International Hol... (LSE:CTI)
Historical Stock Chart
From May 2023 to May 2024